Zentalis Pharmaceuticals Llc
$ 3.72
-5.82%
03 Jun - close price
- Market Cap 281,186,000 USD
- Current Price $ 3.72
- High / Low $ 3.94 / 3.62
- Stock P/E N/A
- Book Value 3.13
- EPS -1.74
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.28 %
- ROE -0.52 %
- 52 Week High 6.95
- 52 Week Low 1.13
About
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment of various cancers. The company is headquartered in New York, New York.
Analyst Target Price
$6.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-12 | 2026-03-26 | 2025-11-10 | 2025-08-06 | 2025-05-14 | 2025-03-26 | 2024-11-12 | 2024-08-09 | 2024-05-07 | 2024-02-27 | 2023-11-06 | 2023-08-09 |
| Reported EPS | -0.5031 | -0.49 | -0.37 | -0.37 | -0.67 | -0.6138 | -0.56 | -1.24 | 0.14 | -0.93 | -0.79 | -1.85 |
| Estimated EPS | -0.4683 | -0.61 | -0.48 | -0.52 | -0.61 | -0.6817 | -0.87 | -0.83 | -0.74 | -0.92 | -0.94 | -1.02 |
| Surprise | -0.0348 | 0.12 | 0.11 | 0.15 | -0.06 | 0.0679 | 0.31 | -0.41 | 0.88 | -0.01 | 0.15 | -0.83 |
| Surprise Percentage | -7.4311% | 19.6721% | 22.9167% | 28.8462% | -9.8361% | 9.9604% | 35.6322% | -49.3976% | 118.9189% | -1.087% | 15.9574% | -81.3725% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.46 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ZNTL
2026-06-01 21:40:09
Zentalis Pharmaceuticals announced the grant of non-qualified stock options for 191,000 shares to two new employees. These grants were made under the 2022 Employment Inducement Incentive Award Plan, per Nasdaq Listing Rule 5635(c)(4), to incentivize their employment. The options have an exercise price of $3.98, a 10-year term, and vest over four years.
2026-06-01 20:40:37
Zentalis Pharmaceuticals announced inducement grants to two new employees in accordance with Nasdaq Listing Rule 5635(c)(4). These grants, consisting of non-qualified stock options to purchase 30,000 shares of common stock, were approved by the independent compensation committee and are a material inducement for their employment. The options have a 10-year term and vest over four years, with a strike price based on the closing price of Zentalis's common stock on May 29, 2026.
2026-05-28 17:39:52
Zentalis Pharmaceuticals director Shannon Campbell was granted 114,200 restricted stock units (RSUs) as part of the company's Non-Employee Director Compensation Program. These RSUs, which were issued at no purchase price, will vest in three equal installments on the first, second, and third anniversaries of the grant date, contingent on her continued service on the board. Following this grant, Campbell directly owns 114,200 shares.
2026-05-27 20:10:03
Zentalis Pharmaceuticals has announced key appointments to strengthen its commercial leadership. Shannon Campbell has been appointed to the company's board of directors, and Sarah Kelly has been named Senior Vice President of Commercial Strategy. These appointments are expected to enhance Zentalis' strategic direction and commercialization efforts for its pipeline of cancer therapeutics.
2026-05-27 20:10:03
Zentalis Pharmaceuticals (ZNTL) has expanded its Board of Directors from six to seven members, appointing Shannon Campbell as a Class I director. Campbell will serve until the 2027 annual stockholder meeting and will also join the Compensation Committee. She will receive an annual cash retainer of $45,000 for Board service and an additional $7,500 for committee membership, along with an initial grant of 114,200 restricted stock units (RSUs) vesting over three years.
2026-05-27 20:10:03
Zentalis Pharmaceuticals has announced key appointments to strengthen its commercial leadership as it advances its late-stage development program for azenosertib, a WEE1 inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer. Shannon Campbell joins the Board of Directors, bringing extensive experience in oncology commercialization, while Sarah Kelly is appointed as Senior Vice President of Commercial Strategy to lead launch readiness. These strategic hires aim to build the necessary commercial and operational capabilities for the potential market launch of azenosertib.
